ChartRow logo
Data provided bySource: Twelve Data
CHYM
$32.97-3.85%
as of close, Nov 17, 2026
☾ AH $32.97 -3.85%
PeersBSYPAYCUMANHDOCUGWRE
Share this page

CHYM financial statements

The full income statement, balance sheet, and cash-flow statement for Chime Financial Inc. (CHYM), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

YoY +32.1%
$2.6B TTM$718M Q3 '26
FY23FY24FY25TTM
Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

YoY +36.3%
$2.4B TTM$646.1M Q3 '26
FY23FY24FY25TTM
Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

YoY n/m
$48M TTM$34.3M Q3 '26
FY23FY24FY25TTM
Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

YoY n/m
$80.3M TTM$43.7M Q3 '26
FY23FY24FY25TTM
Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

YoY n/m
$0.20 TTM$0.11 Q3 '26
FY23FY24FY25TTM
Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

YoY +621.0%
$453.6M TTM$126.1M Q3 '26
FY23FY24FY25TTM
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

YoY +36.8%
$37.5M TTM$5.1M Q3 '26
FY23FY24FY25TTM
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

YoY +778.6%
$416.1M TTM$121M Q3 '26
FY23FY24FY25TTM
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

YoY +7.6%
392.9M TTM400.1M Q3 '26
FY23FY24FY25TTM
Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every CHYM chart on Trends →

Shares outstanding (point-in-time)

2025-06 371.7M2025-09 374.6M2025-12 374.6M2026-03 384.1M2026-06 378.6M2026-09 383.8M+3.2% over 5 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23
Revenue2.19B+30.7%1.67B+30.9%1.28B
1.92B+31.2%1.47B+38.4%1.06B
Cost of revenue263M+26.8%208M-5.6%220M
2.96B+94.0%1.53B+18.0%1.29B
Research & development935M+202.0%310M+19.5%259M
Selling, general & administrative1.15B+64.6%697M+16.4%599M
General & administrative512M+189.0%177M+14.4%155M
Selling & marketing635M+22.2%520M+17.1%444M
Restructuring
32.6M——
Provision for credit losses77.7M+131.6%33.5M0.00
Operating income-1.04B-1572.0%-62.2M+73.6%-236M
Other non-operating income30.9M-21.8%39.5M+20.3%32.8M
Pre-tax income-1.01B-4338.7%-22.7M+88.8%-203M
Income tax831K-68.2%2.61M+1015.4%234K
-1.01B-3884.9%-25.3M+87.5%-203M
Net income to common-1.01B-3884.9%-25.3M+87.5%-203M
-$4.27-994.9%-$0.39+87.9%-$3.22
EPS (basic)-$4.27-994.9%-$0.39+87.9%-$3.22
Weighted-avg shares (basic)236M+264.0%64.9M+2.9%63.1M
Weighted-avg shares (diluted)236M+264.0%64.9M+2.9%63.1M
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23
1.76B+36.4%1.29B—
Cash & equivalents466M+38.1%338M+40.9%240M
Accounts receivable258M+19.3%216M—
Prepaid expenses107M+51.5%70.5M—
1.96B+34.5%1.46B—
Property, plant & equipment94.3M+1.7%92.7M—
Operating lease right-of-use83.4M+69.1%49.3M—
Goodwill27.5M+0.0%27.5M—
Intangible assets
27.5M——
Other non-current assets3.35M-25.1%4.48M—
388M+3.5%375M—
Accounts payable38.7M+7.9%35.8M—
Accrued liabilities81.4M-19.0%100M—
Current lease liability11.4M-27.7%15.7M—
563M+12.2%502M—
Long-term debt
0.00——
Non-current lease liability123M+53.0%80.6M—
Operating lease liability (total)
135M——
Other non-current liabilities51.7M+12.1%46.1M—
1.40B+172.6%-1.93B+1.2%-1.95B
Preferred stock0.000.00—
Additional paid-in capital4.78B+1002.0%433M—
Retained earnings-3.37B-42.7%-2.36B—
Accumulated other comprehensive income172K-15.3%203K—
Total equity incl. non-controlling
1.40B——
Total liabilities & equity1.96B+34.5%1.46B—
Common shares issued
—67.0M—
Common shares outstanding
—67.0M—
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23
52.8M-17.7%64.1M+141.0%-157M
Depreciation & amortization30.0M+18.2%25.4M+96.1%12.9M
Share-based compensation1.07B+3488.2%29.8M+14.6%26.0M
Change in receivables43.0M+6.6%40.3M-24.4%53.3M
Change in payables2.83M-79.3%13.7M+912.8%1.35M
Other operating activities-94.0K-196.9%97.0K-92.5%1.30M
-290M-734.5%45.7M-72.7%167M
Capital expenditure28.7M+98.5%14.5M-48.0%27.8M
Free cash flow24.1M-51.6%49.7M+126.9%-184M
Acquisitions0.00-100.0%13.3M0.00
368M+80528.9%456K-45.8%842K
Long-term debt issued0.000.000.00
Long-term debt repaid0.000.000.00
Common stock issued0.000.000.00
Common stock repurchased77.5M+8061.9%950K+1457.4%61.0K
Dividends paid0.000.000.00
Net change in cash131M+18.6%110M+879.2%11.3M
Interest paid330K-29.3%467K+764.8%54.0K
Income taxes paid1.13M-48.3%2.18M+692.0%275K
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23
Market cap
9.43B——
P/S
4.3×——
P/B
6.7×——
P/FCF
391.9×——
FCF yield
0.26%——
Source filing10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025—$98.9M$83.5M$26.2M$68.00$122.00

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: CHYM’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CHYM filings on SEC EDGAR → Not investment advice.